MCID: ANG054
MIFTS: 66

Angina Pectoris

Categories: Blood diseases, Cardiovascular diseases, Oral diseases, Rare diseases

Aliases & Classifications for Angina Pectoris

MalaCards integrated aliases for Angina Pectoris:

Name: Angina Pectoris 40 36 37 17 32
Prinzmetal's Variant Angina 12 74 52 71
Prinzmetal Angina 12 52 15
Variant Angina 12 52 54
Coronary Artery Vasospasm 52 71
Angina Pectoris, Variant 43 71
Prinzmetal's Angina 12 17
Angina Inversa 12 52
Angina 42 62
Variant Angina Pectoris 12
Vasospastic Angina 52

Classifications:



External Ids:

Disease Ontology 12 DOID:0111151
KEGG 36 H01632
MeSH 43 D000788
ICD10 32 I20 I20.1 I20.9
UMLS 71 C0002963 C0010073 C2931193

Summaries for Angina Pectoris

NIH Rare Diseases : 52 Prinzmetal's variant angina (PVA) is characterized by recurrent episodes of chest pain (angina ) that usually occur when a person is at rest, between midnight and early morning. "Typical" angina, by contrast, is often triggered by physical exertion or emotional stress. Episodes of PVA can be very painful, and may last from several minutes to thirty minutes. In some cases the pain may spread from the chest to the head, shoulder, or arm. The pain associated with PVA is caused by a spasm in the arteries that supply blood to the heart muscle (coronary arteries ). This results in an obstruction of blood flow. In some people, persistent spasms increase the risk for serious complications such as a life-threatening arrhythmia or heart attack . PVA most commonly occurs in people who smoke and people who have high cholesterol or high blood pressure . In many cases it occurs for unknown reasons in otherwise healthy people. In some cases it may be triggered by alcohol withdrawal, stress, exposure to cold, certain medications, or use of stimulants such as cocaine. The diagnosis of PVA involves findings on an electrocardiogram , evidence of the spasms on angiogram , and relief of sudden symptoms with medicines called nitrates . Treatment during an episode to relieve pain and shorten its duration involves sublingual nitroglycerin (a nitrate). Treatment to reduce the frequency of episodes and possibly reduce the risk of serious complications involves calcium channel blockers or long-acting nitrates . For people with PVA who smoke, quitting smoking can lead to a significant decrease in the frequency of episodes. While most people with PVA do not experience serious complications, it is a chronic condition that needs to be monitored over time.

MalaCards based summary : Angina Pectoris, also known as prinzmetal's variant angina, is related to intermittent claudication and aortic valve insufficiency, and has symptoms including other and unspecified angina pectoris An important gene associated with Angina Pectoris is EDN1 (Endothelin 1), and among its related pathways/superpathways are cAMP signaling pathway and Folate Metabolism. The drugs Glyburide and Amiodarone have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are cardiovascular system and growth/size/body region

Disease Ontology : 12 A coronary artery vasospasm characterized by spasms of the coronary arteries that occur while at rest, generally late at night or early in the morning, resulting in severe chest pain with preserved exercise capacity.

MedlinePlus : 42 Angina is chest pain or discomfort you feel when there is not enough blood flow to your heart muscle. Your heart muscle needs the oxygen that the blood carries. Angina may feel like pressure or a squeezing pain in your chest. It may feel like indigestion. You may also feel pain in your shoulders, arms, neck, jaw, or back. Angina is a symptom of coronary artery disease (CAD), the most common heart disease. CAD happens when a sticky substance called plaque builds up in the arteries that supply blood to the heart, reducing blood flow. There are three types of angina: Stable angina is the most common type. It happens when the heart is working harder than usual. Stable angina has a regular pattern. Rest and medicines usually help. Unstable angina is the most dangerous. It does not follow a pattern and can happen without physical exertion. It does not go away with rest or medicine. It is a sign that you could have a heart attack soon. Variant angina is rare. It happens when you are resting. Medicines can help. Not all chest pain or discomfort is angina. If you have chest pain, you should see your health care provider. NIH: National Heart, Lung, and Blood Institute

KEGG : 36 Angina pectoris is defined as cardiac-induced pain arising from a lack of myocardial oxygen. "Angina" is used to describe clinical symptoms such as discomfort in the chest, jaw, shoulder, back, or arms that are induced by physical exertion or emotional stress and subside with rest or treatment with nitroglycerin. Angina is clinically classified into stable angina (SA) and unstable angina (UA). SA is a chronic medical condition while UA is an acute coronary syndrome. Among the causes of angina pectoris, the most common is coronary artery disease (CAD). At the cellular level, angina pectoris is a result of increased myocardial oxygen demand or decreased myocardial oxygen supply.

PubMed Health : 62 About angina: Angina (an-JI-nuh or AN-juh-nuh) is chest pain or discomfort that occurs if an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also can occur in your shoulders, arms, neck, jaw, or back. Angina pain may even feel like indigestion. Angina isn't a disease; it's a symptom of an underlying heart problem. Angina usually is a symptom of coronary heart disease (CHD). CHD is the most common type of heart disease in adults. It occurs if a waxy substance called plaque (plak) builds up on the inner walls of your coronary arteries. These arteries carry oxygen-rich blood to your heart.

Wikipedia : 74 Variant angina, and less commonly vasospastic angina, angina inversa, coronary vessel spasm, or coronary... more...

Related Diseases for Angina Pectoris

Diseases related to Angina Pectoris via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 886)
# Related Disease Score Top Affiliating Genes
1 intermittent claudication 31.5 IL6 CRP ACE
2 aortic valve insufficiency 31.2 NPPB CRP ACE
3 cardiogenic shock 31.1 PLAT NPPB IL6 CRP
4 proteasome-associated autoinflammatory syndrome 1 30.9 INS IL6 CRP
5 aortitis 30.9 IL6 CRP
6 aortic aneurysm, familial abdominal, 1 30.8 IL6 CRP ACE
7 raynaud disease 30.8 EDN1 CRP ACE
8 necrotizing fasciitis 30.7 IL6 F3 CRP
9 mitral valve stenosis 30.7 NPPB F3 CRP ACE
10 ileus 30.7 INS IL6 CRP
11 granulomatous angiitis 30.6 CRP ACE
12 anterolateral myocardial infarction 30.6 PLAT NPPB ACE
13 kawasaki disease 30.6 NPPB IL6 CRP
14 atrioventricular block 30.6 TNNI3 PIK3C2A NPPB ACE
15 pain agnosia 30.6 KNG1 IL6 ADRB1
16 cardiac arrest 30.6 PIK3C2A NPPB KNG1 ACE
17 takayasu arteritis 30.6 IL6 F3 EDN1 CRP
18 mediastinitis 30.6 INS CRP
19 mitral valve insufficiency 30.6 TNNI3 NPPB CRP ACE
20 end stage renal failure 30.5 NPPB IL6 CRP ACE
21 first-degree atrioventricular block 30.5 CRP ACE
22 peripheral nervous system disease 30.5 INS IL6 CRP ACE
23 cardiac rupture 30.5 PLAT CRP
24 rheumatic fever 30.5 NPPB IL6 ACE
25 pericarditis 30.5 TNNI3 NPPB IL6 CRP ACE
26 coronary stenosis 30.5 TNNI3 PIK3C2A NPPB IL6 CRP APOA1
27 complex regional pain syndrome 30.4 IL6 EDN1 ACE
28 gallbladder disease 30.4 INS CRP APOA1
29 right bundle branch block 30.4 TNNI3 NPPB ACE
30 eisenmenger syndrome 30.4 PLAT EDN1
31 thrombocytosis 30.4 IL6 F3 CRP
32 toxic shock syndrome 30.4 IL6 F3 CRP
33 antiphospholipid syndrome 30.4 PLAT F3 CRP
34 atrial standstill 1 30.4 TNNI3 NPPB ADRB1 ACE
35 constrictive pericarditis 30.4 TNNI3 NPPB CRP ACE
36 myocardial stunning 30.3 TNNI3 KNG1 EDN1 ACE
37 thrombophlebitis 30.3 PLAT F3 CRP
38 lipid metabolism disorder 30.3 LPA INS IL6 CRP APOA1 ACE
39 leptin deficiency or dysfunction 30.3 INS IL6 CRP
40 fibromyalgia 30.3 INS IL6 CRP
41 inferior myocardial infarction 30.3 PLAT PIK3C2A NPPB
42 exanthem 30.2 PIK3C2A IL6 F3 CRP ACE
43 prediabetes syndrome 30.2 INS IL6 CRP ACE
44 left bundle branch hemiblock 30.2 TNNI3 PIK3C2A NPPB CRP ACE
45 lemierre's syndrome 30.2 F3 CRP
46 mental depression 30.1 IL6 HTR1B CRP
47 purpura 30.1 IL6 F3 CRP ACE
48 rheumatic heart disease 30.1 NPPB IL6 ACE
49 anxiety 30.1 INS IL6 HTR1B CRP
50 carotid stenosis 30.1 NOS3 LPA CRP ACE

Comorbidity relations with Angina Pectoris via Phenotypic Disease Network (PDN):


Esophagitis Hypertension, Essential
Intermediate Coronary Syndrome Mitral Valve Disease

Graphical network of the top 20 diseases related to Angina Pectoris:



Diseases related to Angina Pectoris

Symptoms & Phenotypes for Angina Pectoris

UMLS symptoms related to Angina Pectoris:


angina pectoris, other and unspecified angina pectoris

MGI Mouse Phenotypes related to Angina Pectoris:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.21 ACE ADRB1 APOA1 CRP EDN1 F3
2 growth/size/body region MP:0005378 10.03 ACE ADRB1 EDN1 F3 HTR1B IL6
3 endocrine/exocrine gland MP:0005379 9.97 ACE ADRB1 APOA1 EDN1 HTR1B IL6
4 adipose tissue MP:0005375 9.95 ACE ADRB1 HTR1B IL6 INS NOS3
5 homeostasis/metabolism MP:0005376 9.93 ACE ADRB1 APOA1 CRP EDN1 F3
6 mortality/aging MP:0010768 9.73 ACE ADRB1 EDN1 F3 HTR1B IL6
7 muscle MP:0005369 9.32 ADRB1 EDN1 F3 HTR1B IL6 INS

Drugs & Therapeutics for Angina Pectoris

PubMed Health treatment related to Angina Pectoris: 62

Treatments for angina include lifestyle changes, medicines, medical procedures, cardiac rehabilitation (rehab), and other therapies . The main goals of treatment are to: Reduce pain and discomfort and how often it occurs Prevent or lower your risk for heart attack and death by treating your underlying heart condition Lifestyle changes and medicines may be the only treatments needed if your symptoms are mild and aren't getting worse. If lifestyle changes and medicines don't control angina , you may need medical procedures or cardiac rehab . Unstable angina is an emergency condition that requires treatment in a hospital.

Drugs for Angina Pectoris (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 580)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Glyburide Approved Phase 4 10238-21-8 3488
2
Amiodarone Approved, Investigational Phase 4 1951-25-3 2157
3
Trimetazidine Approved, Investigational Phase 4 5011-34-7
4
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
5
Acarbose Approved, Investigational Phase 4 56180-94-0 441184
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Udenafil Approved, Investigational Phase 4 268203-93-6 6918523
8
Thrombin Approved, Investigational Phase 4
9
Pantoprazole Approved Phase 4 102625-70-7 4679
10
Glimepiride Approved Phase 4 93479-97-1 3476
11
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
12
Spironolactone Approved Phase 4 1952-01-7, 52-01-7 5833
13
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
14
Simvastatin Approved Phase 4 79902-63-9 54454
15
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
16
Morphine Approved, Investigational Phase 4 57-27-2 5288826
17
Naloxone Approved, Vet_approved Phase 4 465-65-6 5284596
18
Metoclopramide Approved, Investigational Phase 4 364-62-5 4168
19
Glucagon Approved Phase 4 16941-32-5
20
Pravastatin Approved Phase 4 81093-37-0 54687
21
Molsidomine Approved, Investigational Phase 4 25717-80-0
22
Dobutamine Approved Phase 4 34368-04-2 36811
23
Bivalirudin Approved, Investigational Phase 4 128270-60-0 16129704
24
Nicotinamide Approved, Investigational Phase 4 98-92-0 936
25
Fenofibrate Approved Phase 4 49562-28-9 3339
26
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
27
Zinc Approved, Investigational Phase 4 7440-66-6 32051
28
Liraglutide Approved Phase 4 204656-20-2 44147092
29
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
30
Pioglitazone Approved, Investigational Phase 4 111025-46-8 4829
31
Digoxin Approved Phase 4 20830-75-5 30322 2724385
32
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 158781 130881
33
Insulin glargine Approved Phase 4 160337-95-1
34
Felodipine Approved, Investigational Phase 4 72509-76-3 3333
35
Eptifibatide Approved, Investigational Phase 4 188627-80-7 123610
36
Cefpirome Approved Phase 4 84957-29-9 5479539
37
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478
38
Moxifloxacin Approved, Investigational Phase 4 151096-09-2, 354812-41-2 152946
39
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
40
Empagliflozin Approved Phase 4 864070-44-0
41
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
42
Cangrelor Approved Phase 4 163706-06-7 9854012
43
Fondaparinux Approved, Investigational Phase 4 104993-28-4
44
Tamsulosin Approved, Investigational Phase 4 106133-20-4 129211
45
Eplerenone Approved Phase 4 107724-20-9 150310 443872
46
Bezafibrate Approved, Investigational Phase 4 41859-67-0 39042
47
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
48
Nimodipine Approved, Investigational Phase 4 66085-59-4 4497
49
Peppermint oil Approved, Investigational Phase 4 8006-90-4
50
Peppermint Approved Phase 4

Interventional clinical trials:

(show top 50) (show all 1725)
# Name Status NCT ID Phase Drugs
1 Efficacy Study of Atorvastatin to Treat Variant Angina Unknown status NCT00620204 Phase 4 atorvastatin
2 A Randomized, Double-blind, Placebo-controlled Trial of Dan-shen Extract in Patients With Stable Angina Pectoris Unknown status NCT02870764 Phase 4 Dan-shen extract;Placebo
3 Impact of Paclitaxel-eluting Stent for Small Coronary Artery Disease Unknown status NCT00955214 Phase 4
4 Research on the Clinical Effect of Xuefu Zhuyu Decoction in Treating Unstable Angina. Unknown status NCT03179618 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction
5 Efficacy and Safety of Salvianolate Injection in Elderly Patients With Unstable Angina Pectoris: a Parallel, Double Blind, Randomized, Controlled, Multi-center Trial. Unknown status NCT03037047 Phase 4 0.9% Sodium Chloride Injection;salvianolate injection
6 Coronary Angioplasty in Octogenarians With Emergent Coronary Syndromes: The Octogenarians Study Unknown status NCT02126202 Phase 4
7 Randomized Study on SCS for the Treatment of Refractory Angina Pectoris Unknown status NCT00121654 Phase 4
8 Research on the Clinical Effect of Effective Prescription in Treating Unstable Angina. Unknown status NCT03171597 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Xuefu Zhuyu Decoction;Gualou Xiebai Banxia Decoction & Danshen Decoction;Shuanghe Decoction
9 Research on the Clinical Effect of Gualou Xiebai Banxia Decoction Compounded With Danshen Decoction in Treating Unstable Angina. Unknown status NCT03179514 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Gualou Xiebai Banxia Decoction & Danshen Decoction
10 Research on the Clinical Effect of Shuanghe Decoction in Treating Unstable Angina. Unknown status NCT03179527 Phase 4 Anti-Platelet Drugs;Lipid Regulating Drugs;Coronary Vasodilator;Shuanghe Decoction
11 The Effects of Pravastatin and Rosuvastatin on the Tissue Characteristics and Morphology of Coronary Plaques in Patients With Stable Angina Pectoris Unknown status NCT01325818 Phase 4 pravastatin, rosuvastatin
12 Effect of Ticagrelor on Adenosine-Induced Coronary Flow Reserve in Patients With Microvascular Angina Unknown status NCT02284048 Phase 4 ticagrelor
13 Safety of Amiodarone and Ranolazine Together in Patients With Stable Angina Unknown status NCT01558830 Phase 4 ranolazine;placebo
14 Effect of Vitamin C Infusion on Coronary Reperfusion Indexes Unknown status NCT01090895 Phase 4 Vitamin C;Placebo
15 Effect of Ranolazine on Activity Level in Patients With Angina After FFR Based Deferred Intervention Unknown status NCT03044964 Phase 4 Ranolazine;Placebo
16 Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina: A Randomised, Double-blind, Placebo-controlled Clinical Trial Unknown status NCT02280850 Phase 4 Guanxin Shutong Capsule;Placebo Capsule;nitroglycerine
17 Comparison of Low-dose Heparin Versus Standard Dose Heparin During Coronary Interventions (DEDICA Trial) Unknown status NCT01694459 Phase 4 Low-dose heparin;Standard dose heparin
18 Multicenter Trial on Clinical Utility of Acarbose in Patients With Ischemic Heart Disease Accompanied by Abnormal Glucose Regulation Unknown status NCT00858676 Phase 4 acarbose
19 Clinical Study of Combination Therapy for Angina of Coronary Heart Disease With Aspirin and Salvianolate Injection Based on Population Pharmacokinetics and Therapeutic Effect:A Randomized, Controlled Trial Unknown status NCT02694848 Phase 4 Salvianolate injection;Aspirin
20 Prospective Randomised Study Comparing Efficacy of Treatment Coronary In-stent Restenosis Using Drug Eluting Paclitaxel-coated Balloon and Drug Eluting Stent With Everolimus. Unknown status NCT01735825 Phase 4
21 Open-label Clinical Pharmacokinetic Study of Cardionat®, Capsules 250 mg (JSC Nizhpharm, Russia) Using in Health Athlete Volunteers Unknown status NCT02758912 Phase 4 оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg
22 A Comparative Study to Assess the Efficacy of Nicorandil+Atenolol vs Atenolol in Treatment naïve Patients of Chronic Stable Angina. Unknown status NCT01397994 Phase 4 Nicorandil;Atenolol
23 Bedside Testing of the CYP2C19 Gene to Asses Effectiveness of Clopidogrel in Coronary Artery Disease Patients Treated With Percutaneous Coronary Intervention : Individualized Antiplatelet Drugs Treatment to Improve Prognosis Unknown status NCT01823185 Phase 4 clopidogrel;Ticagrelor or prasugrel
24 Comparative Study of the Effects of Telmisartan and Nebivolol on 24-h Ambulatory Blood Pressure and Arterial Stiffness in Patients With Arterial Hypertension Unknown status NCT02057328 Phase 4 TELMISARTAN;NEBIVOLOL
25 the Effect of Nifedipine Controlled Release Tablets in Hypertensive Patients on Chronic Maintenance Hemodialysis and the Influence of Hemodialysis on the Plasma Concentration of Nifedipine Unknown status NCT01021501 Phase 4 nifedipine controlled release tablets
26 Evaluation of Radial Strain Versus Fractional Shortening and Fractional Area Change for Assessment of Left Ventricular Function in Transesophageal Echocardiography Unknown status NCT01080495 Phase 4
27 Comparison of Vascular Remodeling Between Different Antianginal Medication Evaluated by Noninvasive ECG-gated Fundus Photographic Evaluation Unknown status NCT01162902 Phase 4 Diltiazem treated group;Bisoprolol treated group;Candesartan treated group
28 A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial Unknown status NCT02609698 Phase 4 3 months DAPT;6 months DAPT
29 Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients With Stable Angina, NSTEMI and STEMI Undergoing PCI Unknown status NCT02012140 Phase 4 ticagrelor
30 Understanding of Chest Pain in Microvascular Disease Proved by Cardiac Magnetic Resonance Image Unknown status NCT01769482 Phase 4 Udenafil;placebo
31 The Safety and Efficacy of Intensive Statin Therapy in PCI Patient With Acute Coronary Syndrome Unknown status NCT01372839 Phase 4 Atorvastatin;Statin
32 A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients Unknown status NCT01120327 Phase 4 Placebo;Amlodipine
33 Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization. Unknown status NCT02099617 Phase 4
34 Efficacy Study of Nicorandil on Neointima After Coronary Drug-eluting Stent Implantation in Patients With Diabetic Mellitus Unknown status NCT02328521 Phase 4 Nicorandil;nicorandil placebo
35 A Morbi-Mortality and Remodeling Study With Valsartan in Patients With Hypertension and Cardiovascular Disease Unknown status NCT00133328 Phase 4 valsartan
36 Effects of Sodium Tanshinone IIA Sulfonate on Left Ventricular Remodeling in Patients With ST-segment Elevation Myocardial Infarction Following Percutaneous Coronary Intervention Unknown status NCT02524964 Phase 4 sodium tanshinone IIA sulfonate
37 Ranolazine for the Treatment of sYmPtoms of PaLpitations in patiEnts With Ischemic Heart Disease - The RYPPLE Trial Unknown status NCT01495520 Phase 4 Ranolazine;Placebo
38 The Randomly Controlled Clinical Trial of the Association Between Very Small Embryonic-like Stem Cells and the Prognosis of Coronary Artery Disease Patients Unknown status NCT01633359 Phase 4 Intensive statin;Routine statin
39 A Prospective Multicenter Trial Evaluating Helios Biodegradable Polymer Sirolimus-eluting Stent Safety and Effectiveness in Treatment of Coronary Artery Disease Unknown status NCT01880879 Phase 4
40 Ischemia In Hemodialysed Patients And Outcome: Ivabradine Versus Carvedilol. A Randomized, Double Blind Study Unknown status NCT01425164 Phase 4 Ivabradine;Carvedilol
41 TWice overnIght High-dose ranoLazIne Pretreatment for preventinG Myocardial iscHemic Damage in Patients With Stable Angina Undergoing percuTaneous Coronary Intervention Unknown status NCT01491061 Phase 4 Ranolazine;Placebo
42 Ranolazine, Ethnicity and the Metabolic Syndrome - REMS Study Unknown status NCT01304095 Phase 4 Ranolazine
43 Impairment of Gastric Emptying During Acute Phase of Myocardial Infarction. Impact on Oral Antiplatelet Treatment Efficacy. The GASTRIM Study. Unknown status NCT02251249 Phase 4 Paracetamol concentration time curve from 0 to 120 min
44 Impact of Stent Platform on Shear Stress Distribution and Subsequent Vessel Healing After Drug-eluting Stent Implantation (SHEAR DES) Unknown status NCT01942044 Phase 4
45 A Double-Blind, Placebo-Controlled Study of Escitalopram in the Prevention of Depression in Patients With Acute Coronary Syndrome Unknown status NCT00140257 Phase 4 Escitalopram
46 A Randomized, Double-blind, Multi-centered, Placebo-controlled Trial to Examine Effects of Heart-protecting Musk Pill on Clinical Outcome in Patients With Chronic Stable Coronary Artery Disease Unknown status NCT01897805 Phase 4 Heart-protecting Musk Pill;Placebo
47 Single-center Randomized Controlled Study of Omeprazole and Pantoprazole Antiplatelet Effect of Clopidogrel Clinical Randomized Controlled Trials Unknown status NCT01735227 Phase 4 omeprazole;Pantoprazole
48 Assessment of Coronary Flow Reserve by Doppler Flow WIre in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Differences Between the Loading Dose of Prasugrel and Ticagrelor . Unknown status NCT02032303 Phase 4 Ticagrelor loading;Prasugrel loading
49 Randomised, Double-blind, Placebo-controlled Trial of IVabradine in Patients With Acute Coronary Syndrome: Effects of the If Current Inhibitor Ivabradine or rEduction of Inflammation maRkers in Patients With Acute Coronary Syndrome Unknown status NCT00815100 Phase 4 Ivabradine;Placebo
50 Sleep Disordered Breathing in TIA/Ischemic Stroke: Effects on Short- and Long-term Outcome and CPAP Treatment Efficacy: an Open, Observational, Clinical, Multicentre Trial With a Randomized Arm Unknown status NCT01097967 Phase 4

Search NIH Clinical Center for Angina Pectoris

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Amlodipine
Amlodipine Besylate
Diltiazem
Diltiazem Hydrochloride
Diltiazem maleate
DITIAZ
Felodipine
Isradipine
Nicardipine
Nicardipine hydrochloride
Nifedipine
Nisoldipine
Verapamil
Verapamil hydrochloride

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Angina Pectoris cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: angina pectoris, variant

Genetic Tests for Angina Pectoris

Anatomical Context for Angina Pectoris

MalaCards organs/tissues related to Angina Pectoris:

40
Heart, Testes, Endothelial, Spinal Cord, Lung, Bone, Kidney

Publications for Angina Pectoris

Articles related to Angina Pectoris:

(show top 50) (show all 19135)
# Title Authors PMID Year
1
Efficacy and safety of Xinnaoning capsule in treating chronic stable angina (qi stagnation and blood stasis syndrome): Study protocol for a multicenter, randomized, double-blind, placebo-controlled trial. 61 42
31374015 2019
2
Trimetazidine in angina and poor muscle function: protocol for a randomized controlled study. 42
31205105 2019
3
Magnetic Resonance Perfusion or Fractional Flow Reserve in Coronary Disease. 42
31216398 2019
4
Endothelial nitric oxide synthase T-786C mutation, a reversible etiology of Prinzmetal's angina pectoris. 54 61
20211321 2010
5
Impact of periprocedural biomarker elevation on mortality in stable angina pectoris patients undergoing elective coronary intervention: a systematic review and meta-analysis including 24 666 patients. 61
31609755 2020
6
Correlation of plasma soluble suppression of tumorigenicity-2 level with the severity and stability of coronary atherosclerosis. 61
32040025 2020
7
Clinical usefulness of instantaneous wave-free ratio for the evaluation of coronary artery lesion with prior myocardial infarction: A multi-center study. 61
31890864 2020
8
Temporal trends in incidence and outcome of acute coronary syndrome. 61
32034482 2020
9
New potential modulators of CYP4F2 enzyme activity in angina pectoris: hsa-miR-24-3p and hsa-miR-34a-5p. 61
31694408 2020
10
Effects of a Cardiac Rehabilitation Program Versus Usual Care on Cardiopulmonary Function in Patients With Cardiac Syndrome X. 61
31869312 2020
11
A new approach to the diagnosis and treatment of atherosclerosis: the era of the liposome. 61
31525463 2020
12
[Impact of cardiovascular risk factors in the Extremadura population: HERMEX cohort contributions for a preventive strategy]. 61
30638699 2020
13
Transcriptomics and metabolomics reveal the cardioprotective effect of Compound Danshen tablet on isoproterenol-induced myocardial injury in high-fat-diet fed mice. 61
31479707 2020
14
Coronary Involvement in Behçet's Disease: what are its Risks and Prognosis? (Rare Cases and Literature Review). 61
31241876 2020
15
Refractory Angina: From Pathophysiology to New Therapeutic Nonpharmacological Technologies. 61
31918927 2020
16
Glyco-metabolic control, inflammation markers, and cardiovascular outcomes in type 1 and type 2 diabetic patients on insulin pump or multiple daily injection (italico study). 61
31642581 2020
17
A case of fatal acebutolol poisoning: an illustration of the potential of molecular networking. 61
30997571 2020
18
Acupuncture on treating angina pectoris: A systematic review. 61
31914030 2020
19
Efficacy and safety of Guhong injection for treating coronary microvascular disease: study protocol for a randomized controlled trial. 61
31931853 2020
20
Chinese Medicine She-Xiang-Xin-Tong-Ning, Containing Moschus, Corydalis and Ginseng, Protects from Myocardial Ischemia Injury via Angiogenesis. 61
31931593 2020
21
The correlation between trimethylamine N-oxide, lipoprotein ratios, and conventional lipid parameters in patients with unstable angina pectoris. 61
31894847 2020
22
Huoxue Wentong Formula ameliorates myocardial infarction in rats through inhibiting CaMKII oxidation and phosphorylation. 61
31938036 2020
23
Clinical Impact of High-Sensitivity Cardiac Troponin T on the Chronic Phase of Stable Angina after a Successful Initial Percutaneous Coronary Intervention. 61
31903004 2020
24
Marked differences in prediabetes and diabetes associated comorbidities between men and women - epidemiological results from a general population-based cohort aged 6-80 years - the LEAD (Lung, hEart, sociAl, boDy) study. 61
31997311 2020
25
Coronary Angiography for Follow-up of Heart Transplant Recipients: Usefulness of the Gensini Score. 61
32008508 2020
26
Metabolic and Cognitive Effects of Ranolazine in Type 2 Diabetes Mellitus: Data from an in vivo Model. 61
32023991 2020
27
Relationship of systemic pentraxin-3 values with coronary plaque components on optical coherence tomography and post-percutaneous coronary intervention outcomes in patients with stable angina pectoris. 61
31805452 2020
28
Effectiveness of Enhanced External Counterpulsation Treatment on Symptom Burden, Medication Profile, Physical Capacity, Cardiac Anxiety, and Health-Related Quality of Life in Patients With Refractory Angina Pectoris. 61
31929322 2020
29
Feasibility and Clinical Significance of In Vivo Cholesterol Crystal Detection Using Optical Coherence Tomography. 61
31619064 2020
30
The association between heart diseases and suicide: a nationwide cohort study. 61
31960499 2020
31
Meta-analysis of C-Reactive Protein and Risk of Angina Pectoris. 61
32014245 2020
32
[A comparative analysis of quality of life between surgical and interventional treatment in patients with complex coronary heart disease]. 61
31937052 2020
33
Spinal Cord Stimulation for Refractory Angina Pectoris. 61
31755913 2020
34
Ranolazine may exert its beneficial effects by increasing myocardial adenosine levels. 61
31834840 2020
35
Increased sarcoplasmic/endoplasmic reticulum calcium ATPase 2a activity underlies the mechanism of the positive inotropic effect of ivabradine. 61
31912915 2020
36
Efficacy of Aspirin in the Primary Prevention of Cardiovascular Diseases and Cancer in the Elderly: A Population-Based Cohort Study in Korea. 61
31755069 2020
37
Characterization of chemical profile and quantification of representative components of DanLou tablet, a traditional Chinese medicine prescription, by UHPLC-Q/TOF-MS combined with UHPLC-TQ-MS. 61
31911285 2019
38
Comparison of nutrient intakes by nutritional anemia and the association between nutritional anemia and chronic diseases in Korean elderly: Based on the 2013-2015 Korea National Health and Nutrition Examination Survey Data. 61
31814930 2019
39
A Rare Case of Vasospastic Angina Presenting with Inferior Lead ST-segment Elevation and Ventricular Fibrillation in the Absence of Coronary Obstruction: A Case Report. 61
31942263 2019
40
Health-related quality of life and readmission of patients with cardiovascular disease in South Korea. 61
31847706 2019
41
Deoxyribonucleic Acid Repair Activity Is Associated with Healed Coronary Plaque Rupture by Optical Coherence Tomography. 61
31367899 2019
42
Association of Nutritional Assessment by Phase Angle With Mortality in Kidney Transplant Patients in an 8-Year Follow-Up. 61
31476959 2019
43
Lipoprotein apheresis - Shortening of treatment intervals reduces cardiovascular events: Case reports. 61
31818444 2019
44
Pseudo-Wellens syndrome, acute pancreatitis, and an anomalous coronary artery: a case report. 61
31884973 2019
45
Superiority of high sensitivity cardiac troponin T vs. I for long-term prognostic value in patients with chest pain; data from the Akershus cardiac Examination (ACE) 3 study. 61
31899280 2019
46
Intra-aortic balloon pump in acute chest pain and cardiogenic shock - a long-term follow-up. 61
31476881 2019
47
Prevalence of Established Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus in the UK. 61
31583647 2019
48
Management of paroxysmal atrial flutter that occurred in an outpatient prior to dental surgery: a case report. 61
31801491 2019
49
Somatic health in the Indigenous Sami population - a systematic review. 61
31262241 2019
50
A systematic review of the effectiveness and safety of Chinese herbal medicine formula Gualou Xiebai Banxia (GLXBBX) decoction for the treatment of stable angina pectoris. 61
31860998 2019

Variations for Angina Pectoris

Expression for Angina Pectoris

LifeMap Discovery
Genes differentially expressed in tissues of Angina Pectoris patients vs. healthy controls: 35
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 EGR3 early growth response 3 Blood + 4.04 0.001
Search GEO for disease gene expression data for Angina Pectoris.

Pathways for Angina Pectoris

GO Terms for Angina Pectoris

Cellular components related to Angina Pectoris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.65 PLAT NPPB KNG1 INS IL6 F3
2 endoplasmic reticulum lumen GO:0005788 9.46 KNG1 INS IL6 APOA1
3 extracellular region GO:0005576 9.36 PLAT NPPB LPA KNG1 INS IL6

Biological processes related to Angina Pectoris according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 cellular protein metabolic process GO:0044267 9.73 KNG1 INS IL6 APOA1
2 heart contraction GO:0060047 9.55 TNNI3 ACE
3 negative regulation of blood coagulation GO:0030195 9.54 KNG1 EDN1
4 positive regulation of renal sodium excretion GO:0035815 9.52 NPPB EDN1
5 positive regulation of urine volume GO:0035810 9.51 NPPB EDN1
6 negative regulation of blood vessel diameter GO:0097756 9.49 INS CRP
7 negative regulation of lipid storage GO:0010888 9.48 IL6 CRP
8 body fluid secretion GO:0007589 9.46 NPPB EDN1
9 acute-phase response GO:0006953 9.43 INS IL6 CRP
10 neutrophil mediated immunity GO:0002446 9.4 IL6 ACE
11 negative regulation of hydrolase activity GO:0051346 9.37 NOS3 APOA1
12 negative regulation of proteolysis GO:0045861 9.33 PLAT KNG1 INS
13 regulation of systemic arterial blood pressure by endothelin GO:0003100 9.32 NOS3 EDN1
14 regulation of blood vessel diameter GO:0097746 9.13 NPPB NOS3 ACE
15 regulation of blood pressure GO:0008217 8.92 NPPB NOS3 EDN1 ACE

Molecular functions related to Angina Pectoris according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.13 NPPB INS EDN1
2 signaling receptor binding GO:0005102 9.02 PLAT NPPB KNG1 EDN1 APOA1

Sources for Angina Pectoris

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....